The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylated mutant p53 interacts with p300 to promote transactivation of ephrin-B2 and enhances ATP-binding cassette subfamily G member 2 levels, thereby promoting chemoresistance.256”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Longati, P., Jia, X., Eimer, J., Wagman, A., Witt, M.-R., Rehnmark, S., Verbeke, C., Toftgård, R., Löhr, M., & Heuchel, R. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-95 · Cited by 394
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Research works printed but not linked: 45
- Cayuso J, Xu Q, Wilkinson DG . Mechanisms of boundary formation by Eph receptor and ephrin signaling. Dev Biol 2015; 401: 122–131. · DOI
- Tallquist MD, Soriano P, Klinghoffer RA . Growth factor signaling pathways in vascular development. Oncogene 1999; 18: 7917–7932. · DOI
- Pasquale EB . Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005; 6: 462–475. · DOI · Paper page
- Senturk A, Pfennig S, Weiss A, Burk K, Acker-Palmer A . Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration. Nature 2011; 472: 356–360. · DOI
- Pasquale EB . Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165–180. · DOI · Paper page
- Brantley-Sieders DM, Chen J . Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 2004; 7: 17–28. · DOI
- Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424–8429. · DOI · Paper page
- Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42–46. · DOI · Paper page
- Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157. · DOI · Paper page
- Blandino G, Levine AJ, Oren M . Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477–485. · DOI · Paper page
- Peled A, Zipori D, Rotter V . Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res 1996; 56: 2148–2156.
- Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V . The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis 2014; 35: 1196–1208. · DOI
- Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 2012; 26: 830–845. · DOI · Paper page
- Yadav VK, Kumar A, Mann A, Aggarwal S, Kumar M, Roy SD et al. Engineered reversal of drug resistance in cancer cells—metastases suppressor factors as change agents. Nucleic Acids Res 2014; 42: 764–773. · DOI
- Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992; 12: 1035–1053.
- Razick S, Magklaras G, Donaldson IM . iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics 2008; 9: 405. · DOI · Paper page
- Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011; 39: D561–D568. · DOI · Paper page
- Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E et al. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 2011; 10: 4330–4340. · DOI
- Debnath S, Chatterjee S, Arif M, Kundu TK, Roy S . Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction. J Biol Chem 2011; 286: 25076–25087. · doi:10.1074/jbc.m110.205328
- Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002; 94: 934–939. · DOI
- Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012; 119: 4565–4576. · DOI
- Zhu MM, Tong JL, Xu Q, Nie F, Xu XT, Xiao SD et al. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One 2012; 7: e41763. · DOI
- Wu HC, Chang CH, Peng HY, Chen GD, Lai CY, Hsieh MC et al. EphrinB2 induces pelvic-urethra reflex potentiation via Src kinase-dependent tyrosine phosphorylation of NR2B. Am J Physiol Renal Physiol 2011; 300: F403–F411. · doi:10.1152/ajprenal.00520.2010
- Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820–5828. · DOI · Paper page
- Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012; 417: 679–685. · DOI
- Avizienyte E, Frame MC . Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17: 542–547. · DOI · Paper page
- Freed-Pastor WA, Prives C . Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268–1286. · DOI · Paper page
- Muller PA, Vousden KH . p53 mutations in cancer. Nat Cell Biol 2013; 15: 2–8. · DOI · Paper page
- Peled A, Schwartz D, Elkind NB, Wolkowicz R, Li R, Rotter V . The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene 1996; 13: 1677–1685.
- Davidson BA, Rubatt JM, Corcoran DL, Teoh DK, Bernardini MQ, Grace LA et al. Differential angiogenic gene expression in TP53 wild-type and mutant ovarian cancer cell lines. Front Oncol 2014; 4: 163.
- Han JD, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 2004; 430: 88–93. · DOI · Paper page
- Nakayama A, Nakayama M, Turner CJ, Hoing S, Lepore JJ, Adams RH . Ephrin-B2 controls PDGFRbeta internalization and signaling. Genes Dev 2013; 27: 2576–2589. · DOI
- Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010; 465: 487–491. · DOI · Paper page
- Bong YS, Lee HS, Carim-Todd L, Mood K, Nishanian TG, Tessarollo L et al. ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc Natl Acad Sci USA 2007; 104: 17305–17310. · DOI
- Stahl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A et al. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis 2013; 4: e454. · DOI
- Bush JA, Li G . Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002; 98: 323–330. · DOI
- Li RX, Chen ZH, Chen ZK . The role of the EPH receptors in the cancer-related epithelial-mesenchymal transition Running title: Eph receptors and EMT. Chin J Cancer 2013; 33: 231–240. · DOI
- Kim JH, Peacock MR, George SC, Hughes CC . BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis 2012; 15: 497–509. · DOI
- Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D et al. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res 2008; 68: 8667–8672. · doi:10.1158/0008-5472.can-08-2614
- Jeong H, Mason SP, Barabasi AL, Oltvai ZN . Lethality and centrality in protein networks. Nature 2001; 411: 41–42. · DOI · Paper page
- He X, Zhang J . Why do hubs tend to be essential in protein networks? PLoS Genet 2006; 2: e88. · DOI · Paper page
- Albert R, Jeong H, Barabasi AL . Error and attack tolerance of complex networks. Nature 2000; 406: 378–382. · DOI · Paper page
- Wuchty S, Almaas E . Peeling the yeast protein network. Proteomics 2005; 5: 444–449. · DOI · Paper page
- Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1–6. · DOI · Paper page
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25–29. · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297
Shen, M., Xu, Z., Xu, W., Jiang, K., Zhang, F., Ding, Q., Xu, Z., & Chen, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1161-8 · Cited by 215
Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94
Metadata
- Authors
- Alam, S. K., Yadav, V. K., Bajaj, S., Datta, A., Dutta, S. K., Bhattacharyya, M., Bhattacharya, S., Debnath, S., Roy, S., Boardman, L. A., Smyrk, T. C., Molina, J. R., Chakrabarti, S., Chowdhury, S., Mukhopadhyay, D., & Roychoudhury, S.
- Venue
- Cell Death & Differentiation
- Published
- 2015-10-23
- Volume
- 23
- Issue
- 4
- Pages
- 707-722
- ISSN
- 1350-9047
- 1476-5403
- Cited by
- 91
- References
- 7
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.